This information packet contains general information regarding the Fellows Program. For more information visit www.avac.org/fellows.
Advocacy Fellows Program Information Packet
AVAC Advocacy Fellows Host Commitment Form
The Host Organization Commitment Form is designed to help specify the commitments of prospective applicants and their host organization if selected for the Advocacy Fellows Program. Download as a PDF or Word document.
For more information visit www.avac.org/fellows.
AVAC Advocacy Fellows Program 2024-2025 Application Social Media Tile
The AVAC Advocacy Fellows Program is now recruiting its 13th class and is looking for the next cohort of emerging and mid-career advocates to explore what’s needed to address epidemics and progress global public health equity.
Want to help spread the word? Download our shareable social media tile.
Resources & Recommended Reading for Prospective 2022 Applicants for the Fellows Program
This resource package directs prospective applicants of the Fellows Program to online resources on HIV prevention research and general information on HIV and AIDS. For more information on the Fellows program, visit www.avac.org/fellows.
Frequently Asked Questions for Host Organizations
This resource is a FAQ document for prospective host organizations of the Fellows Program. For more information visit www.avac.org/fellows.
AVAC Advocacy Fellows Quick Guide for Applicants
Brief two-pager outlining the AVAC Advocacy Fellows program. More information available at www.avac.org/fellows.
Tales from Two Cities: HIV and STI research highlights from Brisbane and Chicago
August 3, 2023 at 9am ET
TCA’s invited experts will share their highlights and reflections on the HIV and STI-related science presented at two major global health conferences. These conferences include IAS 2023, taking place in Brisbane, Australia July 23 – 26 and the 2023 STI and HIV World Congress happening in Chicago (United States) from July 24 – July 27.
Speakers include:
Dr. Aniruddha Hazra – University of Chicago
Nyaradzo M Mgodi – University of Zimbabwe
Roger Pebody – NAM, Aidsmap.com
Charlie Peterson – University of Illinois – Chicago
Including Pregnant and Lactating Populations in HIV Prevention Research
Pregnancy and the post-partum period after giving birth are times of heightened HIV risk. Cisgender women are two to three times more likely to acquire HIV during pregnancy and four times more likely post-partum than otherwise. Women who acquire HIV during pregnancy have an 18 percent chance of transmitting HIV to their newborn, which goes up to a 27 percent chance if they acquire HIV while breastfeeding.
Yet, HIV prevention options for pregnant and lactating populations (PLP) are limited, and their inclusion in research inadequate and hence evidence gaps can be seen across the research landscape for new prevention products. Most biomedical HIV prevention research excludes PLP, and those who become pregnant during a trial are typically stopped from further use of the study drug. PLP include cisgender women, transgender men and those who identify as gender non-binary who are able to get pregnant. For transgender and gender-diverse pregnant people, evidence gaps are even further magnified.
The exclusion of Pregnant and Lactating People (PLP) from research results in:
- A lack of data on dosing and maternal and fetal safety
- Limitations around prescribing potentially beneficial interventions
- Exclusion from potential direct benefits of research participation
- Delays and discrepancies in health policies and programs
There is growing consensus for the greater inclusion of PLP in HIV prevention research as a public health ethical imperative, but action and a paradigm shift is needed from a variety of stakeholders to promote ethical inclusion rather than presumptive exclusion of pregnant women from clinical drug trials.
“Excluding pregnant women from clinical trials doesn’t eliminate risk, it simply shifts the risk from research studies to the doctor’s office, where pregnant women receive treatments rarely supported by robust data about how they will respond and whether the drugs are effective in pregnancy.” – Dr Anne Lyerly, PHASES, Source: Undark 2020
The Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Project guidance identifies conceptual shifts for the ethical framing of research as shown here.

Ethical Shifts in the Framing of Research in PLP (PHASES, 2020)
The resources below provide background on the issue, updates on progress toward the inclusion of PLP in HIV prevention research and explore advocacy to accelerate this progress.
- Advancing HIV Prevention Research in Pregnant and Lactating People (PLP): Think Tank Report & Action Plan — The work of the AVAC/PHASES think tank to advance HIV prevention research with pregnant and lactating people was importantly grounded in a trio of conceptual frameworks.
- Pregnancy and Neonatal Safety Outcomes of Timing of Initiation of Daily Oral Tenofovir Disoproxil Fumarate and Emtricitabine Pre-exposure prophylaxis for HIV Prevention (CAP016): An open-label, randomised, non-inferiority trial — Appearing in the Lancet HIV, this research provides much-needed safety data to allow for a more informed choice during pregnancy to protect mother and baby from the long-term effects of HIV.
- Advancing HIV Prevention Research in Pregnant and Lactating Populations (PLP): Priority Advocacy Objectives and Next Steps — A four point action plan to advance the inclusion of PLP in clinical research for HIV prevention.
- An Advocate’s Guide to Research in Pregnant and Lactating Populations — A resource that provides background on the need for research in PLP and how advocates can advance inclusion
- Special JIAS Issue — Approaches to enhance and accelerate investigation of new HIV drugs in pregnancy. Guest Editors: Elaine J. Abrams, Martina Penazzato. Published in 2022.
- The History of Reproductive Justice — A video created by In Our Own Voice: National Black Women’s Reproductive Justice Agenda
- Ending the Evidence Gap for Pregnant Women Around HIV/co-infections: A call to action — Guidance for advancing HIV/co-infection research with pregnant women, issued by the PHASES project in 2020
- Research for Informed Choices: Accelerating the study of new drugs for HIV in pregnant and breastfeeding women: A call to action — A multi-stakeholder action plan for promoting the inclusion of pregnant women in HIV, issued by WHO, IMPAACT and IAS in 2021
- State of the HIV Prevention Evidence Base — Data on HIV prevention options for PLP and upcoming research presented by Dr. Lisa Noguchi at the AVAC/PHASES Think Tank in 2022
- Approaches to Enhance and Accelerate Investigation of new HIV Drugs in Pregnancy — A JIAS supplement published in 2022
- Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap — An article that outlines PLP involvement in recent and ongoing HIV PrEP trials and advocacy for further inclusion, written by Dr. Dvora Joseph Davey et. al and published in 2022
- Why Are So Few Drugs Tested for Safety in Pregnancy? — An article from the Undark independent magazine that provides a summary of the history and regulatory changes with regards to why so few drugs are tested for safety in pregnancy. Published in 2020
Press Release
AVAC Applauds the Selection of Dr. Jeanne Marrazzo as New Director of NIAID
Wednesday, August 2, 2023
AVAC enthusiastically applauds the selection of Jeanne Marrazzo, MD, to serve as the new director of the NIH’s National Institute of Allergy and infectious Disease (NIAID). Dr. Marrazzo brings unparalleled leadership and research expertise to this pivotal role at NIAID, which oversees some of the largest investments to advance research on HIV and sexually transmitted infections in the world, at such a critical moment in global health science and politics.
“Jeanne has been a pioneer in both HIV prevention and STI research and advocacy for many years. This news of her selection as NIAID Director just does not get any better,” said Mitchell Warren, AVAC’s Executive Director. “Given her distinguished career, NIAID’s selection signals a commitment to pursuing a research agenda that is aimed squarely at defeating HIV while safeguarding principles that advance global health equity. Moreover, her appointment reflects the important intersection of science, policy, communications and advocacy that has defined her career thus far.”
“Perhaps most importantly, her longtime championship of community engagement and person-centered research provides a fantastic foundation for this role,” said Manju Chatani-Gada, AVAC’s Director for Partnerships & Capacity Strengthening. “She has always been accessible and provided time, mentorship and support to civil society advocates in breaking down and interpreting science. Ultimately, it is not just what science gets supported at NIAID, but how the science happens and how it is communicated, and Jeanne is the right leader at the right time to build on Dr. Fauci’s legacy.”
Dr. Marrazzo’s research included landmark investigations of pre-exposure prophylaxis (PrEP) for cisgender women as well as discovery and implementation science research focused on complex issues including hormonal contraception and HIV, antimicrobial resistance in gonorrhea, and other efforts especially as they effect women’s health and livelihoods and exacerbate the impact of infectious diseases. She provided pioneering leadership of the Microbicide Trials Network’s groundbreaking Vaginal and Oral Interventions to Control the Epidemic (VOICE) study, one of the most complex HIV prevention studies ever designed and conducted.
“Jeanne is a remarkable physician, researcher and advocate. We are so optimistic about her ability to connect the dots—between HIV prevention, sexual and reproductive health, and pandemic preparedness, and help solve for the threats of disparities in access, stigma, discrimination and criminalization of key populations,” Warren added.
Dr. Marrazzo will be the first new director of NIAID in nearly 40 years and the first woman in this position. She will also be the first openly gay director of any institute at the NIH. The position was held by Dr. Anthony Fauci, whose vision, passion and commitment to ending the AIDS epidemic and advancing global health research has been an inspiration to AVAC and to so many. Dr. Marrazzo is expected to assume the post as NIAID Director later this year.
###
About AVAC: AVAC is an international non-profit organization that leverages its independent voice and global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity. Follow AVAC on Twitter @HIVpxresearch; find more at www.avac.org and www.prepwatch.org.
Our Take: Are the UN Declaration on PPPR and the Pandemic Accord going in the right direction?
The last few weeks have been filled with high-level negotiations among UN Member States on the way forward for global pandemic prevention, preparedness, and response (PPPR) efforts. Below, please find an analysis of the negotiated language to date in the Pandemic Accord, and the UN Declaration on PPPR, and their implications for equity in PPPR. These analyses were conducted by AVAC and partners working in collaboration to track progress toward equity in these agreements and develop an advocacy agenda for provisions in both that ensure equity in global health advances. The Declaration is an agreement that involves heads of state and potentially a role for all ministries of government. The Pandemic Accord is being negotiated by members of the WHO to strengthen PPPR.
The Pandemic Accord: A look at negotiations to date
The first draft of the WHO-led Pandemic Accord was released in May, containing edits to the zero draft from the Member States. As expected, edits from high-income countries introduced challenges to equity provisions in the text— particularly provisions aimed at ensuring that agreements to share access to data on pathogens is paired with commitments to also share the benefits developed from research using those data (termed pathogen access and benefits sharing). Other equity provisions that were challenged include intellectual property, and language on how the world should allocate vaccines, therapeutics, and diagnostics in the event of a global pandemic threat. Throughout the document, certain high-income Member States inserted caveats or wording, such as “encourage” or “as appropriate”, which would make implementation voluntary or compliance more subjective. Other phrases to weaken the agreements, such as replacing “commit to” with “recognize the importance of”, were also inserted.
Negotiations so far have resulted in weaker, alternative language to several key articles than in the so-called zero draft of the accord. These include articles on technology transfer, the Pathogen Access and Benefit Sharing (PABS) System, health workforce strengthening, and the proposed Supply Chain & Logistics Network. There are, however, some clauses that have been strengthened. Global R&D networks, laboratory networks for genomic surveillance, knowledge translation, and the harmonization of regulation to accelerate WHO pre-approval and authorization all have stronger commitments and more details than before. You can find the first draft here and a closer analysis of the changes made between the zero and first draft here.
The UN Declaration on PPPR: What’s in the Zero Draft?
The zero draft of the UN Declaration on PPPR, set to be adopted at the High-Level Meeting on September 20, was released in June.
Many provisions in the draft Declaration are positive, recognizing and affirming key points related to human rights and inclusive provisions that prioritize vulnerable and marginalized populations. The draft recognizes vaccine inequity as a vital concern, affirms key principles of equity and non-discrimination and the need to ensure adequate support for both health workers and the WHO. However, there are very few, if any, concrete targets set, leaving little to hold countries accountable. Missing from the Declaration, in particular the section on Overarching Health Related Issues, is the need for countries to prioritize and commit to building on the global responses to ongoing epidemics, including HIV/AIDS, TB, malaria, polio, other neglected disease outbreaks such as Ebola, Marburg, and cholera, and antimicrobial resistance (AMR).
This is a missed opportunity with enormous implications. It signals a troubling and serious global inability to build on existing health and community infrastructures, integrate responses, and avoid erecting isolated pillars in global health architecture. Many of the capacities needed for PPPR already exist in the response to these other health threats. They can and must be expanded and strengthened for broader pandemic preparedness. In addition, the history of the responses to HIV/AIDS, TB, and malaria have made clear that community leadership in the response and civil society engagement are essential to achieve success in PPPR. The current response to existing health threats, which through trial and error have built resilient and effective systems, should serve as the foundation for any future pandemic preparedness and response efforts. The Declaration’s silence on this issue is gravely concerning.
The Declaration’s clauses relating to agreements on pandemic-related tools and products are strong, and notably stronger than those in the first draft of the Pandemic Accord. But equity provisions, and access to those tools, could be strengthened further, by including compulsory licensing and transfer of know-how when necessary.
It’s vital for advocates to engage with these processes, and leverage their power to influence the emerging architecture in global health. Decisions being made now will have implications for years to come. And the voices of advocates are having an influence. For example, the US government’s contribution to the current draft of the UN declaration recently added specific recommendations from AVAC and partners on the inclusion of Good Participatory Practice. It’s up to all of us to make sure GPP and other provisions that ensure equity in global health are in place when the drafts become final.
You can find the Declaration zero draft here and see our analysis and the changes we call for here.
What’s Next
These negotiations are setting the direction for pandemic readiness for years to come. As discussions continue in the weeks and months ahead, it’s imperative for advocates and countries to be raising their voices and calling for language and commitments that will ensure equity in PPPR. Building on the lessons the world has learned from ongoing epidemics, and integrating the response must be a priority to ensure the tragic results of inequity in global health are not repeated, again and again.
AVAC will be sharing these analyses with our partners and governments with whom we work with. For more background, read AVAC’s Advocates Guide for PPPR. And you can take action now by sending these resources to your country’s UN representatives and other influential voices in your networks!